Evox Therapeutics Overview
- Founded
-
2016
- Status
-
Private
- Employees
-
135
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$95M
- Investors
-
13
Evox Therapeutics General Information
Description
Developer of exosome-based therapeutics designed to treat various life-threatening rare diseases with profound implications for human health. The company's therapeutics use nucleic acid and protein delivery technology to harness and engineer the natural trafficking capabilities of extracellular vesicles, enabling healthcare providers to leverage proprietary targeting, manufacturing processes and purification methods.
Contact Information
Website
www.evoxtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- Oxford Science Park, Medawar Centre
- 2nd Floor East Building, Robert Robinson Avenue
- Oxford OX4 4HG
- England, United Kingdom
+44 01865 000000
Evox Therapeutics Timeline
Evox Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 18-Feb-2021 | $95M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Grant | 22-Mar-2019 | 00.000 | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series B) | 03-Sep-2018 | $45.6M | $60.2M | 000.00 | Completed | Generating Revenue |
| 1. Seed Round | 10-May-2016 | $14.6M | $14.6M | 0000 | Completed | Clinical Trials - Phase 1 |
Evox Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Preferred | 000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| A Preferred | 000,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
| Ordinary | 224,496 | $0.013743 | $61.84 | $61.84 | 1x | $61.84 | 22.16% |
Evox Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of exosome-based therapeutics designed to treat various life-threatening rare diseases with profound implicati
Biotechnology
Oxford, United Kingdom
135
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000
cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000000000000
Brisbane, CA
000
As of 0000
00000
000000000
00000
000000
exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repr
0000 000000000
Ghent, Belgium
00
As of 0000
00000
00000000000
00000
Add Comparison
Evox Therapeutics Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sangamo Therapeutics | Formerly VC-backed | Brisbane, CA | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Venture Capital-Backed | Ghent, Belgium | 00 | 00000 | 00000000000 | 00000 |
| 000000 0000 | Corporation | Miramar, FL | 00 | 000000000 - | ||
| 000000 | Venture Capital-Backed | Seattle, WA | 00 | 00000 | 0000000000 | 00000 |
| 00000 000000000000 | Venture Capital-Backed | Woburn, MA | 0 | 00.00 | 0000000000 0 | 00.00 |
Evox Therapeutics Patents
Evox Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202118946-D0 | Engineered extracellular vesicles with improved cargo delivery | Pending | 23-Dec-2021 | ||
| GB-202107182-D0 | Nanoparticle delivery system for production of engineered extracellular vesicles | Pending | 19-May-2021 | ||
| GB-202105925-D0 | Modified extracellular vesicles (evs) with improved half-life | Pending | 26-Apr-2021 | ||
| GB-202015399-D0 | Engineered extracellular vesicles displaying enhanced pharmacokinetics | Inactive | 29-Sep-2020 | 000000000 | |
| GB-202010278-D0 | Extracellular vesicles with improved half-life | Inactive | 03-Jul-2020 | A61K9/5068 |
Evox Therapeutics Executive Team (5)
Evox Therapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Amrit Nagpal | Redmile Group | Board Member | 000 0000 |
| Antonin de Fougerolles Ph.D | Evox Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Chau Khuong | Self | Board Member | 000 0000 |
| John McHutchison MD | Self | Board Member | 000 0000 |
| Kevin Raidy | Cowen Healthcare Investments | Board Observer | 000 0000 |
Evox Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Evox Therapeutics Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| OrbiMed | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Skyviews Life Science | Venture Capital | Minority | 000 0000 | 000000 0 | |
| The Invus Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Duchenne UK | Corporation | 000 0000 | 000000 0 | ||
| Innovate UK | Government | 000 0000 | 000000 0 |